ClinicalTrials.gg
Not yet recruitingNCT07088289Updated Nov 4, 2026

VR Mindfulness for People With HIV and Substance Use

An interventional study of TRIPP in HIV and Substance Use (Drugs, Alcohol), sponsored by University of Texas at Austin. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Texas at Austin · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 4, 2026Sponsor changedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Substance-Related Disorders by University of Texas at Austin — 2 open to participants now, 2 under way, none of them phase 3. Substance-Related Disorders · University of Texas at Austin.

Planned enrollment
10th of 10
30 · median 97
Started
2026
with 1 other
No phase
8 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Substance-Related Disorders by University of Texas at Austin, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 8 with no phase, and was the 9th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

2 of the 10 studies in Substance-Related Disorders by University of Texas at Austin are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Substance-Related Disorders by University of Texas at Austin, or all of them as a file.
02

Study summary

The goal of this clinical trial is to explore whether a virtual reality (VR) mindfulness app is acceptable, appropriate, and feasible for supporting people with HIV and substance use problems.

Participants will:

  • Use a VR headset with a mindfulness app at home;
  • Complete three online surveys over three months;
  • Take part in an individual interview or focus group to share their experiences.
03

Conditions studied

  • HIV
  • Substance Use (Drugs, Alcohol)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to speak, read, and write in English
  • Aged 18 years or older
  • Diagnosed with
  • Currently prescribed ART therapy
  • Reporting moderate to high risk related to alcohol, opioids, nicotine, cannabis, or stimulant use (score of 4 or higher on the Alcohol, Smoking, and Substance Involvement Screening Test - ASSIST). Participants may also use other substances, but the primary risk must fall within these categories, as these have the strongest research support for mindfulness-based interventions.
  • Having stable housing that allow using VR safely
  • Willing to provide contact information for at least one person whom the study team can reach if the participant becomes unreachable after repeated attempts

Exclusion criteria

Exclusion Criteria:

  • Living in institutionalized settings or unsheltered
  • Terminal illness with a of less than 6 months
  • Planning to move out of the area in the next eight weeks
  • Engaging in regular mindfulness practice outside of TRIPP
  • Experiencing fear of closed spaces or unable to tolerate wearing a VR headset (verified during orientation session)
  • Having visual or auditory impairments or severe physical disabilities that hinder VR use, history of seizures, severe cognitive impairment, severe motion sickness, severe unmanaged psychiatric symptoms, or currently pregnant
  • Participants without home internet access will not be excluded and will be provided either funding for internet service or VR headsets preloaded with TRIPP sessions for offline use.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    VR mindfulness

    Participants in this arm will receive a virtual reality (VR) mindfulness intervention named TRIPP. TRIPP is a commercially available VR mindfulness app designed to promote relaxation, focus, and emotional well-being through immersive, guided experiences. The app combines visual and auditory stimulation, breathwork, meditation, and interactive elements to help users reduce stress and improve mood.

    Behavioral: TRIPP

Interventions

  • BehavioralTRIPP

    In this study, participants will use TRIPP with a VR headset at home, engaging in short mindfulness sessions 3+ times per week for 4-12 weeks.

06

What researchers measure

Primary outcomes

  1. Intervention acceptability as measured by the Acceptability of Intervention Measure

    The Acceptability of Intervention Measure is a 4-item scale that assesses the extent to which participants find the intervention agreeable or satisfactory. Items are rated on a 5-point Likert scale ranging from 1 (Completely disagree) to 5 (Completely agree). Scores are averaged to create a total score, with higher scores indicating greater perceived acceptability of the intervention. Example items include: "I like \[intervention\]" and "\[intervention\] meets my approval."

    Time frame: One-month follow-up

  2. Intervention appropriateness as measured by the Intervention Appropriateness Measure

    The Intervention Appropriateness Measure is a 4-item scale designed to assess how suitable or relevant the intervention is for the target population. Each item is rated from 1 (Completely disagree) to 5 (Completely agree), and a total score is calculated by averaging responses. Higher scores reflect a stronger belief that the intervention is appropriate for the individual's needs or situation. Example items include: "\[intervention\] seems like a good match" and "\[intervention\] seems suitable."

    Time frame: One-month follow up

  3. Intervention feasibility as measured by the Feasibility of Intervention Measure

    The Feasibility of Intervention Measure includes 4 items that measure how practical and doable the intervention seems from the participant's perspective. Participants respond on a 5-point scale from 1 (Completely disagree) to 5 (Completely agree), with higher average scores indicating greater perceived feasibility. Example items include: "\[intervention\] seems implementable" and "\[intervention\] seems easy to use."

    Time frame: One-month follow up

Secondary outcomes

  1. Intervention engagement as measured by VR mindfulness app use frequency

    Engagement with the intervention will be measured by the frequency of VR mindfulness app use, as recorded by the TRIPP app. The system captures the number of times participants launch and complete mindfulness sessions during the study period. Higher session counts reflect greater engagement with the intervention. There is no maximum score, and a higher number of sessions indicates more frequent use of the app.

    Time frame: From enrollment to the end at 12 weeks.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 12 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Feb 2026 → Dec 2026, primary completion May 2027 → Dec 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2025
First posted
Jul 28, 2025
StartEst.
Dec 2026was Feb 2026
Primary completionEst.
Dec 2027was May 2027
CompletionEst.
Dec 2027was Jun 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2026→Dec 2026
Oct 13, 2026
Primary completion
May 2027→Dec 2027
Oct 13, 2026
Study completion
Jun 2027→Dec 2027
Oct 13, 2026
Contact
Study contact changed: •••1457→•••3497; added n•••@tulane.edu · •••3497. See the current contact
Oct 13, 2026
Sponsor
Tulane University→University of Texas at Austin
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Sponsor Tulane University→University of Texas at Austin
    + 1 other change: identifiers
  2. Oct 13, 2026
    Start date Feb 2026→Dec 2026
    Primary completion May 2027→Dec 2027
    Study completion Jun 2027→Dec 2027
    Contact Study contact changed: •••1457→•••3497; added n•••@tulane.edu · •••3497. See the current contact
    + 3 other changes: verification date, responsible party and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07088289
Responsible party
Hang Hai (Associate Professor, University of Texas at Austin) — Principal investigator
First posted
Jul 28, 2025
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Audrey Hang Hai, PhD
Contact
ahai@tulane.edu
(504)862-3497
Ngawang Legshe, DSW, LCSW-BACS
Contact
nlegshe@tulane.edu
(504)862-3497
Audrey Hang Hai, PhD
principal investigator · University of Texas at Austin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion